Terms: = Breast cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
12 results:
1. S100A4 Is Involved in Stimulatory Effects Elicited by the FGF2/fgfr1 Signaling Pathway in Triple-Negative breast cancer (TNBC) Cells.
Santolla MF; Talia M; Maggiolini M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946884
[TBL] [Abstract] [Full Text] [Related]
2. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced breast cancer.
O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
[TBL] [Abstract] [Full Text] [Related]
3. Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
De Nicola I; Guerrieri AN; Penzo M; Ceccarelli C; De Leo A; Trerè D; Montanaro L
Histol Histopathol; 2020 Oct; 35(10):1181-1187. PubMed ID: 32901907
[TBL] [Abstract] [Full Text] [Related]
4. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.
Sundararajan V; Tan M; Tan TZ; Ye J; Thiery JP; Huang RY
Sci Rep; 2019 Jun; 9(1):8295. PubMed ID: 31165775
[TBL] [Abstract] [Full Text] [Related]
5. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Chen L; Qi H; Zhang L; Li H; Shao J; Chen H; Zhong M; Shi X; Ye T; Li Q
BMC Cancer; 2018 Oct; 18(1):1038. PubMed ID: 30359238
[TBL] [Abstract] [Full Text] [Related]
6. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract] [Full Text] [Related]
7. clinical significance of the B7-H4 as a novel prognostic marker in breast cancer.
Huang H; Li C; Ren G
Gene; 2017 Aug; 623():24-28. PubMed ID: 28412458
[TBL] [Abstract] [Full Text] [Related]
8. PI3K/AKT Signaling Regulates H3K4 Methylation in breast cancer.
Spangle JM; Dreijerink KM; Groner AC; Cheng H; Ohlson CE; Reyes J; Lin CY; Bradner J; Zhao JJ; Roberts TM; Brown M
Cell Rep; 2016 Jun; 15(12):2692-704. PubMed ID: 27292631
[TBL] [Abstract] [Full Text] [Related]
9. A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
Hong Q; Yu S; Yang Y; Liu G; Shao Z
Oncotarget; 2014 Jul; 5(13):4779-87. PubMed ID: 24952432
[TBL] [Abstract] [Full Text] [Related]
10. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
11. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma.
Pfister S; Rea S; Taipale M; Mendrzyk F; Straub B; Ittrich C; Thuerigen O; Sinn HP; Akhtar A; Lichter P
Int J Cancer; 2008 Mar; 122(6):1207-13. PubMed ID: 18058815
[TBL] [Abstract] [Full Text] [Related]
12. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Chin K; DeVries S; Fridlyand J; Spellman PT; Roydasgupta R; Kuo WL; Lapuk A; Neve RM; Qian Z; Ryder T; Chen F; Feiler H; Tokuyasu T; Kingsley C; Dairkee S; Meng Z; Chew K; Pinkel D; Jain A; Ljung BM; Esserman L; Albertson DG; Waldman FM; Gray JW
Cancer Cell; 2006 Dec; 10(6):529-41. PubMed ID: 17157792
[TBL] [Abstract] [Full Text] [Related]
